— Know what they know.
Not Investment Advice

ATNX NASDAQ

Athenex, Inc.
1W: -42.1% 1M: -82.5% 3M: -92.8% 1Y: -97.9% 3Y: -99.9% 5Y: -99.9%
$0.20
Last traded 2023-05-24 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $2.3M mcap · 7M float · 3.93% daily turnover

Revenue Segmentation

By Product / Service

By Geography

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$103M -14.4% ▼
5Y CAGR: +22.0%
Gross Profit
$27M -29.3% ▼
5Y CAGR: +15.6%
Operating Income
-$70M +39.2% ▲
Net Income
-$99M +49.1% ▲
EPS (Diluted)
$-15.13 +59.5% ▲
EBITDA
-$72M +39.4% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2018FY2019FY2020FY2021FY2022
Revenue$89M$101M$144M$120M$103M
YoY Growth+134.2%+13.6%+42.6%-16.8%-14.4%
Cost of Revenue$47M$70M$95M$82M$76M
Gross Profit$42M$32M$49M$38M$27M
Gross Margin47.2%31.2%34.0%31.4%26.0%
R&D Expenses$120M$84M$76M$80M$52M
SG&A Expenses$49M$67M$97M$73M$45M
Operating Expenses$169M$151M$173M$153M$97M
Operating Income-$127M-$120M-$124M-$115M-$70M
Operating Margin-142.3%-118.1%-85.7%-95.7%-68.0%
Interest Expense$2M$7M$11M$21M$26M
Income Before Tax-$129M-$125M-$144M-$205M-$99M
Tax Expense$100K$928K$4M-$11M$347K
Net Income-$117M-$126M-$148M-$194M-$99M
Net Margin-131.8%-124.0%-102.8%-161.7%-96.3%
EPS (Diluted)$-36.40$-33.90$-34.89$-37.39$-15.13
EBITDA-$112M-$116M-$132M-$105M-$72M
Shares Outstanding3M4M4M5M7M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms